Filtration, separation and purification company, Pall Corporation, has announced the next step in its collaboration agreement with ARTeSYN Biosolutions, a supplier of single-use components and fluid management technologies.
Under this co-exclusive agreement, Pall Biotech will immediately distribute ARTeSYN’s standard hardware and liner components.
"ARTeSYN valves offer unmatched biopharmaceutical fluid flow control, with a compact, durable single-use design for simple installation and maintenance," notes Michael Gagne, founder and CXO, ARTeSYN Biosolutions.
“This codistribution agreement with ARTeSYN Biosolutions is a critical element of our partnering programme and complements Pall’s existing Allegro integrated single-use portfolio of upstream, downstream and final filling solutions,” said Ed Hoare, Senior Vice President, Pall Biotech.
"The agreement also helps to accelerate the implementation of robust and standardised single-use fluid management and controls, which has been an industry challenge for decades.”
“The adoption of single-use technology continues to grow within the cGMP clinical and commercial manufacturing space. This collaboration reflects our focus on accelerating single-use technology adoption for more efficient production of life saving drugs,” commented Gagne.
“We are excited to work with Pall, a company with which we share similar goals to offer innovative biotech solutions and an outstanding global commercial, technical and validation support network.”